COMPASS Pathways (NASDAQ:CMPS – Free Report) had its target price lowered by HC Wainwright from $60.00 to $45.00 in a research note issued to investors on Thursday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for COMPASS Pathways’ FY2028 earnings at $0.14 EPS and FY2029 earnings at $1.63 EPS.
Several other research analysts also recently commented on CMPS. Royal Bank of Canada reissued an “outperform” rating and issued a $18.00 price target on shares of COMPASS Pathways in a report on Wednesday, January 15th. Maxim Group reduced their price target on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 1st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $30.60.
Get Our Latest Analysis on CMPS
COMPASS Pathways Price Performance
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in CMPS. Jane Street Group LLC boosted its stake in shares of COMPASS Pathways by 72.7% in the fourth quarter. Jane Street Group LLC now owns 51,815 shares of the company’s stock worth $196,000 after buying an additional 21,815 shares during the last quarter. AdvisorShares Investments LLC increased its stake in COMPASS Pathways by 51.8% during the fourth quarter. AdvisorShares Investments LLC now owns 66,602 shares of the company’s stock worth $252,000 after acquiring an additional 22,720 shares during the last quarter. Nantahala Capital Management LLC increased its stake in COMPASS Pathways by 400.0% during the fourth quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company’s stock worth $3,780,000 after acquiring an additional 800,000 shares during the last quarter. Virtus ETF Advisers LLC boosted its position in shares of COMPASS Pathways by 21.4% during the fourth quarter. Virtus ETF Advisers LLC now owns 16,121 shares of the company’s stock worth $61,000 after buying an additional 2,840 shares during the period. Finally, Two Sigma Securities LLC purchased a new position in COMPASS Pathways in the fourth quarter valued at $135,000. 46.19% of the stock is owned by institutional investors and hedge funds.
About COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Featured Articles
- Five stocks we like better than COMPASS Pathways
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- Election Stocks: How Elections Affect the Stock Market
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for COMPASS Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COMPASS Pathways and related companies with MarketBeat.com's FREE daily email newsletter.